In accordance with Article 10 of the Communiqué on Corporate Governance No. II-17.1, which entered into force upon its publication in the Official Gazette dated 3 January 2014 and numbered 28871 by the Capital Markets Board, the Board of Directors has prepared a report dated 24 June 2026 to evaluate the appropriateness of the "Common and Continuous Related Party Transactions" projected to take place during the 2026 fiscal year. The conclusion section of the report is presented below for your information.
Conclusion Section of the Report on the Projected Common and Continuous Related Party Transactions for the 2026 Fiscal Year:
Within the scope of our Company's recurring and continuous related party transactions, it is anticipated that the total transaction value in 2026 with the following related parties:
- Coventya Kimya San. ve Tic. A.Ş.
- MacDermid Performance Solutions Kimyasal Sanayi ve Ticaret A.Ş.
- Alent Enthone Chemistry (Shanghai) Co. Ltd.
- MacDermid Incorporated
may exceed 10% of the cost of sales for purchase transactions, and 10% of the revenue for sales transactions, based on the most recently disclosed annual financial statements. Accordingly, the Company's Board of Directors has prepared the "Board of Directors Report on Recurring and Continuous Related Party Transactions for the 2026 Fiscal Year" in compliance with Article 10 of the Corporate Governance Communiqué (II-17.1), published in the Official Gazette No. 28871 dated January 3, 2014 by the Capital Markets Board. Pursuant to this Report, the terms of the aforementioned transactions will be determined in line with prevailing market conditions and the best interests of the Company, and the applied profit margns will be established by taking into account the Company's field of activity.
This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.